Therapeutic implications of the hyperglutamatergic effects of NMDA antagonists

John H. Krystal, Aysenil Beiger, D. Cyril D’Souza, Amit Anand, Dennis S. Charney, George K. Aghajanian, Bita Moghaddam

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Antagonists of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor produce transient effects in healthy human subjects that resemble symptoms observed in some schizophrenic patients. NMDA antagonists also impair aspects of human corticolimbic information processing in a fashion that resembles deficits associated with schizophrenia, as measured by electrophysiologic and functional neuroimaging paradigms. Although all current antipsychotics block dopamine-2 (D2) receptors, recent studies question the centrality of D2-receptor stimulation to the NMDA-antagonist psychosis. For example, pretreatment with haloperidol fails to attenuate the psychotic effects of ketamine in healthy human subjects. Also, pretreatment with amphetamine fails to increase these effects of ketamine. Both preclinical and clinical studies suggest that subanesthetic doses of NMDA antagonists activate glutamate neurons in the cerebral cortex and hippocampus. Recent preclinical and clinical studies also suggest that drugs that attenuate glutamate release, including group II/III metabotropic glutamate-receptor agonists, drugs that block voltage-dependent ion channels, and serotonin-2A (5-HT2A)-receptor antagonists may attenuate NMDA antagonist effects. To the extent that NMDA antagonist effects provide insight into the pathophysiology of schizophrenia, these novel pharmacologic strategies and others may provide a rationale for the exploration of new treatments that do not involve D2-receptor blockade. If schizophrenia, like NMDA-antagonist effects, involves hyperglutamatergic states, then these novel harmacotherapeutic strategies also may have neuroprotective or neurotrophic consequences that influence the course of schizophrenia.

Original languageEnglish (US)
Pages (from-to)S143-S157
JournalNeuropsychopharmacology
Volume21
DOIs
StatePublished - 1999
Externally publishedYes

Fingerprint

N-Methylaspartate
Schizophrenia
Dopamine Receptors
Ketamine
Therapeutics
Healthy Volunteers
Serotonin 5-HT2 Receptor Antagonists
Mental Processes
Excitatory Amino Acid Agonists
Excitatory Amino Acid Antagonists
Functional Neuroimaging
Metabotropic Glutamate Receptors
Glutamate Receptors
Haloperidol
Amphetamine
Ion Channels
Pharmaceutical Preparations
Cerebral Cortex
Psychotic Disorders
Antipsychotic Agents

Keywords

  • 5-HT2A
  • 907
  • Attention
  • Cognitive function
  • Frontal cortex
  • Glutamate
  • Ketamine
  • Lamotrigine
  • LY354740
  • M100907
  • MDL 100
  • NMDA
  • Pharmacotherapy
  • Schizophrenia
  • Serotonin

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health

Cite this

Krystal, J. H., Beiger, A., D’Souza, D. C., Anand, A., Charney, D. S., Aghajanian, G. K., & Moghaddam, B. (1999). Therapeutic implications of the hyperglutamatergic effects of NMDA antagonists. Neuropsychopharmacology, 21, S143-S157. https://doi.org/10.1016/S0893-133X(99)00102-5

Therapeutic implications of the hyperglutamatergic effects of NMDA antagonists. / Krystal, John H.; Beiger, Aysenil; D’Souza, D. Cyril; Anand, Amit; Charney, Dennis S.; Aghajanian, George K.; Moghaddam, Bita.

In: Neuropsychopharmacology, Vol. 21, 1999, p. S143-S157.

Research output: Contribution to journalArticle

Krystal, JH, Beiger, A, D’Souza, DC, Anand, A, Charney, DS, Aghajanian, GK & Moghaddam, B 1999, 'Therapeutic implications of the hyperglutamatergic effects of NMDA antagonists', Neuropsychopharmacology, vol. 21, pp. S143-S157. https://doi.org/10.1016/S0893-133X(99)00102-5
Krystal JH, Beiger A, D’Souza DC, Anand A, Charney DS, Aghajanian GK et al. Therapeutic implications of the hyperglutamatergic effects of NMDA antagonists. Neuropsychopharmacology. 1999;21:S143-S157. https://doi.org/10.1016/S0893-133X(99)00102-5
Krystal, John H. ; Beiger, Aysenil ; D’Souza, D. Cyril ; Anand, Amit ; Charney, Dennis S. ; Aghajanian, George K. ; Moghaddam, Bita. / Therapeutic implications of the hyperglutamatergic effects of NMDA antagonists. In: Neuropsychopharmacology. 1999 ; Vol. 21. pp. S143-S157.
@article{bb94933b76434ff18ffd421c441cf742,
title = "Therapeutic implications of the hyperglutamatergic effects of NMDA antagonists",
abstract = "Antagonists of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor produce transient effects in healthy human subjects that resemble symptoms observed in some schizophrenic patients. NMDA antagonists also impair aspects of human corticolimbic information processing in a fashion that resembles deficits associated with schizophrenia, as measured by electrophysiologic and functional neuroimaging paradigms. Although all current antipsychotics block dopamine-2 (D2) receptors, recent studies question the centrality of D2-receptor stimulation to the NMDA-antagonist psychosis. For example, pretreatment with haloperidol fails to attenuate the psychotic effects of ketamine in healthy human subjects. Also, pretreatment with amphetamine fails to increase these effects of ketamine. Both preclinical and clinical studies suggest that subanesthetic doses of NMDA antagonists activate glutamate neurons in the cerebral cortex and hippocampus. Recent preclinical and clinical studies also suggest that drugs that attenuate glutamate release, including group II/III metabotropic glutamate-receptor agonists, drugs that block voltage-dependent ion channels, and serotonin-2A (5-HT2A)-receptor antagonists may attenuate NMDA antagonist effects. To the extent that NMDA antagonist effects provide insight into the pathophysiology of schizophrenia, these novel pharmacologic strategies and others may provide a rationale for the exploration of new treatments that do not involve D2-receptor blockade. If schizophrenia, like NMDA-antagonist effects, involves hyperglutamatergic states, then these novel harmacotherapeutic strategies also may have neuroprotective or neurotrophic consequences that influence the course of schizophrenia.",
keywords = "5-HT2A, 907, Attention, Cognitive function, Frontal cortex, Glutamate, Ketamine, Lamotrigine, LY354740, M100907, MDL 100, NMDA, Pharmacotherapy, Schizophrenia, Serotonin",
author = "Krystal, {John H.} and Aysenil Beiger and D’Souza, {D. Cyril} and Amit Anand and Charney, {Dennis S.} and Aghajanian, {George K.} and Bita Moghaddam",
year = "1999",
doi = "10.1016/S0893-133X(99)00102-5",
language = "English (US)",
volume = "21",
pages = "S143--S157",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Therapeutic implications of the hyperglutamatergic effects of NMDA antagonists

AU - Krystal, John H.

AU - Beiger, Aysenil

AU - D’Souza, D. Cyril

AU - Anand, Amit

AU - Charney, Dennis S.

AU - Aghajanian, George K.

AU - Moghaddam, Bita

PY - 1999

Y1 - 1999

N2 - Antagonists of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor produce transient effects in healthy human subjects that resemble symptoms observed in some schizophrenic patients. NMDA antagonists also impair aspects of human corticolimbic information processing in a fashion that resembles deficits associated with schizophrenia, as measured by electrophysiologic and functional neuroimaging paradigms. Although all current antipsychotics block dopamine-2 (D2) receptors, recent studies question the centrality of D2-receptor stimulation to the NMDA-antagonist psychosis. For example, pretreatment with haloperidol fails to attenuate the psychotic effects of ketamine in healthy human subjects. Also, pretreatment with amphetamine fails to increase these effects of ketamine. Both preclinical and clinical studies suggest that subanesthetic doses of NMDA antagonists activate glutamate neurons in the cerebral cortex and hippocampus. Recent preclinical and clinical studies also suggest that drugs that attenuate glutamate release, including group II/III metabotropic glutamate-receptor agonists, drugs that block voltage-dependent ion channels, and serotonin-2A (5-HT2A)-receptor antagonists may attenuate NMDA antagonist effects. To the extent that NMDA antagonist effects provide insight into the pathophysiology of schizophrenia, these novel pharmacologic strategies and others may provide a rationale for the exploration of new treatments that do not involve D2-receptor blockade. If schizophrenia, like NMDA-antagonist effects, involves hyperglutamatergic states, then these novel harmacotherapeutic strategies also may have neuroprotective or neurotrophic consequences that influence the course of schizophrenia.

AB - Antagonists of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor produce transient effects in healthy human subjects that resemble symptoms observed in some schizophrenic patients. NMDA antagonists also impair aspects of human corticolimbic information processing in a fashion that resembles deficits associated with schizophrenia, as measured by electrophysiologic and functional neuroimaging paradigms. Although all current antipsychotics block dopamine-2 (D2) receptors, recent studies question the centrality of D2-receptor stimulation to the NMDA-antagonist psychosis. For example, pretreatment with haloperidol fails to attenuate the psychotic effects of ketamine in healthy human subjects. Also, pretreatment with amphetamine fails to increase these effects of ketamine. Both preclinical and clinical studies suggest that subanesthetic doses of NMDA antagonists activate glutamate neurons in the cerebral cortex and hippocampus. Recent preclinical and clinical studies also suggest that drugs that attenuate glutamate release, including group II/III metabotropic glutamate-receptor agonists, drugs that block voltage-dependent ion channels, and serotonin-2A (5-HT2A)-receptor antagonists may attenuate NMDA antagonist effects. To the extent that NMDA antagonist effects provide insight into the pathophysiology of schizophrenia, these novel pharmacologic strategies and others may provide a rationale for the exploration of new treatments that do not involve D2-receptor blockade. If schizophrenia, like NMDA-antagonist effects, involves hyperglutamatergic states, then these novel harmacotherapeutic strategies also may have neuroprotective or neurotrophic consequences that influence the course of schizophrenia.

KW - 5-HT2A

KW - 907

KW - Attention

KW - Cognitive function

KW - Frontal cortex

KW - Glutamate

KW - Ketamine

KW - Lamotrigine

KW - LY354740

KW - M100907

KW - MDL 100

KW - NMDA

KW - Pharmacotherapy

KW - Schizophrenia

KW - Serotonin

UR - http://www.scopus.com/inward/record.url?scp=0032785487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032785487&partnerID=8YFLogxK

U2 - 10.1016/S0893-133X(99)00102-5

DO - 10.1016/S0893-133X(99)00102-5

M3 - Article

AN - SCOPUS:0032785487

VL - 21

SP - S143-S157

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

ER -